Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane)
Completed
Baxter Healthcare Corporation
Phase 2/Phase 3
2008-02-01
The purposes of this study are to evaluate the efficacy and safety of desflurane (BLM-240) as
an anesthetic agent and to demonstrate the non-inferiority of desflurane to sevoflurane in
term of awakening/recovery from anesthesia.
Previous studies on animals suggest that inhalational anesthetics can reduce vascular tension
in vitro resulting in vasodilation and decrease in blood pressure. This role for inhalational
anesthetics has essential clinical implications such as the condition of sepsis or septic
shock or other shock-associated states during which the blood vessel constricts strongly and
leads to circulation dysfunction. The vasodilation property of these anesthetics including
halothane, isoflurane, sevoflurane, desflurane and enflurane enables them to be better
options than other general anesthetics in many clinical conditions needing the vasculature to
be dilated. The investigators hypothesized that these inhalational anesthetics can evoke
vasodilation measured with ultrasonography during general anesthesia in vivo as the in vitro
studies displayed.
Postoperative Fatigue and Nausea Related to Choice of Anaesthetic Regimens
Completed
Sykehuset Telemark
Phase 4
2010-06-01
The purpose of this study is to establish validated outcome measures for Postoperative
Fatigue and Postoperative nausea, and to compare clinical impact of postanaesthetic symptoms
during first week after Propofol or Desflurane based anaesthesia.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
